
Quarterly ResultAug 13, 2026, 08:52 AM
Biofrontera Q2 Revenue $12.0M, Net Loss Narrows to $0.6M
AI Summary
Biofrontera Inc. reported strong financial results for the second quarter and first half of 2026. Q2 net product revenue increased 32.9% to $12.0 million, and net loss significantly narrowed to $0.6 million from $5.3 million in the prior-year period. Gross margin improved to 80%, reflecting benefits from the October 2025 Strategic Transaction. The company also highlighted progress in its clinical pipeline, including an upcoming PDUFA date for Ameluz in superficial basal cell carcinoma and positive Phase III results for actinic keratoses, while reiterating confidence in achieving cash flow breakeven in 2026.
Key Highlights
- Q2 2026 net product revenue increased 32.9% to $12.0 million.
- Q2 2026 net loss narrowed to $0.6 million from $5.3 million year-over-year.
- Q2 2026 gross margin improved to 80% from 71% in the prior-year period.
- Adjusted EBITDA for Q2 2026 improved by $5.0 million to $(0.2) million.
- H1 2026 net product revenue increased 25.4% to $22.1 million.
- Cash used in operating activities for H1 2026 reduced by 76% to $1.7 million.
- PDUFA date for Ameluz in superficial basal cell carcinoma expected late September 2026.
- Operating expenses declined 11% in Q2 2026.
Price Impact
More from BFRI